2017-02-27,Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results And Provides Corporate Update
2017-02-23,Rexahn Pharmaceuticals Doses First Patient In A Phase IIa Trial Of Supinoxin™ In Patients With Metastatic Triple Negative Breast Cancer
2017-01-20,Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
2017-01-03,Rexahn Pharmaceuticals To Present At Biotech Showcase™ 2017
2016-11-07,Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-31,Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent
2016-10-26,Rexahn Pharmaceuticals Receives U.S. Patent For RX-21101: A Novel Nano-Polymer Conjugate Of Docetaxel For The Targeted Treatment Of Solid Tumors
2016-10-10,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
2016-10-04,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
2016-09-14,Rexahn Announces $6 Million Registered Direct Offering
2016-09-12,Rexahn Pharmaceuticals Initiates Stage 2 Of Phase Ib/IIa Clinical Trial Of RX-3117 In Relapsed Or Refractory Metastatic Pancreatic Cancer
2016-09-07,Rexahn Pharmaceuticals To Present At 18th Annual Rodman & Renshaw  Global Investment Conference On September 12, 2016
2016-08-08,Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results
2016-07-11,Rexahn Pharmaceuticals Strengthens Leadership Team
2016-06-06,Rexahn Pharmaceuticals Presents Clinical Data For Three Novel Targeted Oncology Programs At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-23,Rexahn Pharmaceuticals To Present At The American Society Of Clinical Oncology (ASCO) 2016 Annual Meeting
2016-05-09,Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-04-20,Rexahn Pharmaceuticals Presents Clinical Trial Results For Archexin® At The 2016 American Association For Cancer Research Annual Meeting
2016-04-13,Rexahn Pharmaceuticals To Present At The 2016 American Association For Cancer Research Annual Meeting
2016-03-29,Rexahn Pharmaceuticals Announces Initiation Of Phase Ib/IIa Clinical Trial Of Its Novel Oral Anti-Cancer Therapeutic RX-3117 In The Treatment Of Pancreatic And Bladder Cancer
2016-03-24,Rexahn Pharmaceuticals Presents Additional Data For Supinoxin For The Treatment Of Triple Negative Breast Cancer At The 2016 Targeted Anticancer Therapeutics Congress
2016-03-14,Rexahn Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-26,Rexahn Announces $5 Million Registered Direct Offering
2016-02-12,8 Biotech Stocks Under $10 Poised for Breakouts
2016-02-08,Rexahn Pharmaceuticals Completes Stage 1 And Begins Enrollment In Stage 2 Of Archexin® Phase IIa Clinical Trial In Metastatic Renal Cell Carcinoma
2016-02-01,Rexahn Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference On Monday, February 8, 2016
2016-01-25,Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations At The 2016 Gastrointestinal Cancers Symposium
2016-01-12,New Preclinical Data For Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition
2016-01-11,Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction In A Phase IIa Clinical Study
2016-01-05,Rexahn Pharmaceuticals To Present At Biotech Showcase™ 2016
2015-12-14,Rexahn Pharmaceuticals Announces New Data For Supinoxin™ Showing Potent Tumor Growth Inhibition
2015-11-11,Rexahn Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference On November 18, 2015
2015-11-06,Rexahn Announces $7.0 Million Registered Direct Offering
2015-11-05,Rexahn Pharmaceuticals Reports Interim Clinical Data For Archexin® At The 14th International Kidney Cancer Symposium
2015-11-04,4 Stocks Under $10 Making Big Up Moves on Big Volume
2015-11-03,Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-26,Rexahn Pharmaceuticals Receives U.S. Patent for RX-3117 Anti-Cancer Program
2015-10-14,Rexahn Pharmaceuticals To Present At The 14th Annual BIO Investor Forum
2015-09-28,Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015
2015-09-25,Rexahn Pharmaceuticals To Present Preliminary Clinical Data At The European Cancer Congress 2015
2015-09-23,Rexahn Pharmaceuticals To Present At The 15th Annual Biotech In Europe Investor Forum
2015-09-08,Rexahn Pharmaceuticals To Present At The Biopharm America(TM) 2015 Conference In Boston
2015-08-31,Rexahn Pharmaceuticals To Present At The 17th Annual Rodman And Renshaw Global Investment Conference On September 10, 2015
2015-08-10,Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-14,Rexahn Pharmaceuticals Awarded Patent In Japan For Novel Targeted Cancer Drug Delivery Platform
2015-06-22,Rexahn Announces The Appointment Of Peter Brandt As Chairman Of The Board
2015-06-09,Data On Rexahn's RX-3117 In Non-Small Cell Lung Cancer Presented At 16th International Symposium Of The Purine And Pyrimidine Society
2015-06-08,National Cancer Institute Accepts Rexahn's RX-21101 For Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program
2015-05-29,5 Stocks Under $10 Ready to Spike Higher
2015-05-13,Rexahn Announces Poster Presentations At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-11,Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results And Pipeline Update
2015-04-21,New Data Show Rexahn's Supinoxin(TM) Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model
2015-04-20,Rexahn Identifies RX-3117 Biomarker & Presents Data At The 2015 American Association For Cancer Research Annual Meeting
2015-04-13,Rexahn Pharmaceuticals To Present Data On RX-3117 And Supinoxin(TM) At The 2015 American Association For Cancer Research Annual Meeting
2015-03-18,Rexahn Pharmaceuticals To Present At The 12th Annual BIO Asia International Conference In Tokyo, Japan
2015-03-17,Rexahn Pharmaceuticals Reports Fourth Quarter And Full-Year 2014 Financial Results And Pipeline Update
2015-03-04,Rexahn Pharmaceuticals To Present At The BIO-Europe Spring(R) 2015 Conference In Paris, France
2015-03-02,Rexahn Pharmaceuticals To Present At The ROTH Capital Partners 27th Annual Growth Stock Conference
2015-02-18,Rexahn Pharmaceuticals To Present At The 3rd Annual Sachs Cancer Bio Partnering & Investment Forum In New York
2015-02-09,Rexahn Pharmaceuticals Announces The Publication Of Preclinical Data For Supinoxin(TM) (RX-5902) Demonstrating Mechanism Of Action
2015-02-04,Rexahn Pharmaceuticals Announces The Appointment Of Ely Benaim, M.D., As Chief Medical Officer
2015-02-02,Rexahn Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-07,Rexahn Pharmaceuticals To Present At Biotech Showcase(TM) 2015
2015-01-06,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells
2014-12-04,Rexahn Pharmaceuticals To Present At The Oppenheimer Healthcare Conference On December 10, 2014
2014-12-03,Rexahn Pharmaceuticals Appoints Richard Rodgers To Its Board Of Directors
2014-11-17,Rexahn Pharmaceuticals To Participate In Brean Capital 2014 Life Sciences Summit
2014-11-13,Rexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results And Pipeline Update
2014-11-11,Rexahn Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference On November 18, 2014
2014-10-28,Rexahn Pharmaceuticals To Present At The BIO-Europe(R) Conference In Frankfurt, Germany
2014-09-30,Rexahn Pharmaceuticals To Present At 13th Annual BIO Investor Forum
2014-09-24,Rexahn Receives FDA Orphan Drug Designation For RX-3117 In Treatment Of Pancreatic Cancer
2014-09-23,Rexahn Pharmaceuticals To Present At The 14th Annual Biotech In Europe Investor Forum For Global Partnering And Investment In Basel, Switzerland
2014-09-16,Rexahn Pharmaceuticals To Present At The BioPharm America™ 2014 In Boston, Massachusetts, USA
2014-09-04,Rexahn Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference On September 9, 2014
2014-09-03,Rexahn Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform
2014-08-14,Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results And Pipeline Update
2014-07-18,Rexahn Pharmaceuticals Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors
2014-05-15,Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results And Pipeline Update
2014-05-08,RX-3117 Showed Greater Efficacy (tumor Growth Inhibition) As Compared To Gemcitabine In Four Different Xenograft Animal Models With Gemcitabine Resistant Human Cancer Cell Lines: Colorectal Cancer (Colo205), Small Cell Lung Cancer (H69), Cervical Cancer (CaSki) And Pancreatic Cancer (CTG-0298).
2014-04-21,Rexahn Presents Data From Preclinical Studies Of RX-21101
2014-04-02,Rexahn Pharmaceuticals To Present Data On RX-3117 And RX-21101 At The 2014 American Association For Clinical Research Annual Meeting
2014-03-24,Rexahn Pharmaceuticals Reports Fourth Quarter And Full-Year 2013 Financial Results And Recent Highlights
2014-03-19,3 Stocks Under $10 Making Big Moves
2014-03-17,Rexahn Pharmaceuticals To Present At The 2nd Annual Sachs Cancer Bio Partnering &amp; Investment Forum In New York
2014-03-11,Rexahn Announces Initial Results From Phase I Trial Of SupinoxinTM (RX-5902) For Solid Cancer Tumors
2014-03-07,Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
2014-03-04,Rexahn Pharmaceuticals To Present At The 26th Annual ROTH Conference
2014-03-03,Rexahn Pharmaceuticals Appoints Mark Carthy To Board Of Directors
2014-03-01,Biotech Sector Performance February 2014: Red Hot But...
2014-02-26,4 Biotech Stocks Under $10 Moving Higher
2014-02-06,5 Stocks Under $10 Set to Soar
2014-02-04,Rexahn Pharmaceuticals To Present At The 16th Annual BIO CEO &amp; Investor Conference
2014-01-31,4 Health Care Stocks Under $10 to Watch
2014-01-21,It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
2014-01-15,Rexahn Announces $20 Million Registered Direct Offering
2014-01-14,Rexahn Initiates Phase IIa Clinical Trial Of Archexin&#174; In Patients With Metastatic Renal Cell Carcinoma
2014-01-10,Why Rexahn Pharmaceuticals (RNN) Is Up Today
2014-01-08,Rexahn Initiates Phase Ib Clinical Trial Of RX-3117 For Treatment Of Solid Tumors
2014-01-07,Rexahn Pharmaceuticals To Present At The Biotech Showcase 2014
2013-12-11,Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin TM&#160;(RX-5902)
2013-11-19,Rexahn Pharmaceuticals To Participate In Brean Capital 2013 Life Sciences Summit
2013-11-14,Rexahn Pharmaceuticals Reports Third Quarter Financial Results And Pipeline Update
2013-10-11,Rexahn Announces $5.3 Million At Market Registered Direct Offering
2013-10-10,Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform From Ohio State University
2013-10-03,5 Stocks Under $10 Set to Soar
2013-09-30,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For Novel Anti-Cancer Compound RX-3117
2013-09-12,Rexahn Awarded Patent In Europe For Cancer Drug Archexin&#174;
2013-09-05,Rexahn Pharmaceuticals To Present At The 15th Annual Rodman &amp; Renshaw Global Investment Conference On September 9, 2013
2013-09-04,Rexahn Pharmaceuticals Provides A Clinical Development And Financial Update
2013-08-28,Rexahn Pharmaceuticals Announces Teva Will Not Exercise Its Option To License RX-3117
2013-08-07,Rexahn Pharmaceuticals Initiates Dosing In Phase I Trial Of SupinoxinTM (RX-5902) A Candidate For Treating Solid Cancer Tumors
2013-07-24,Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering
2013-07-17,Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform
2013-07-15,Rexahn Pharmaceuticals Announce IND Submission For RX-3117
2013-07-09,Rexahn Pharmaceuticals Awarded Patent In Japan For Novel Anti-cancer Isoquinolinamine Compounds&#160;&#160;
2013-06-17,Rexahn Awarded U.S. Patent For Novel Anti-Cancer Compounds
2013-05-20,Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Conference
2013-03-11,Rexahn Pharmaceuticals To Present At The 25th Annual ROTH Conference
2013-02-19,Rexahn Pharmaceuticals Provides Key Goals For 2013
2013-01-22,Rexahn Pharmaceuticals Appoints Peter D. Suzdak As Chief Executive Officer
2012-12-17,Rexahn Pharmaceuticals Expands Its Intellectual Property Around Class Of Potent Anti-cancer Isoquinolinamine Compounds
2012-12-04,Rexahn Pharmaceuticals Closes Public Offering For $6,600,000 In Gross Proceeds
2012-11-29,Rexahn Pharmaceuticals Prices Public Offering Of Stock
2012-11-28,Rexahn Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrant
2012-11-28,Teva Pharmaceutical To Increase Ownership In Rexahn
2012-11-21,Rexahn Pharmaceuticals Issued US Patent For Quinoxalinyl-piperazine Compounds
2012-09-26,Rexahn Pharmaceuticals Granted European Patent For Novel Anti-cancer Isoquinolinamine Compounds
2012-09-06,Rexahn Pharmaceuticals To Present At The Rodman &amp; Renshaw 14th Annual Healthcare Conference
2012-09-04,Rexahn Pharmaceuticals Provides Update On 2012 Strategic Goals
2012-08-31,Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta
2012-08-30,Rexahn Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
2012-08-28,Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data For Archexin In Patients With Metastatic Pancreatic Cancer
2012-08-06,Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study Of RX-3117
2012-07-02,Rexahn Submits An Investigational New Drug Application To The FDA For First-in-Class P68 Helicase Inhibitor, RX-5902
2012-05-30,Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anti-Cancer Compound RX-3117
2012-05-08,Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA
2012-03-27,Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-3117 At AACR 103rd Annual Meeting
2012-03-13,Rexahn Pharmaceuticals Enrolls First Subject In Exploratory Phase I Clinical Study Of RX-3117
2012-01-25,Rexahn Pharmaceuticals Publishes New Preclinical Data For Quinoxalinyl-Piperazine Compounds
2012-01-18,Rexahn Pharmaceuticals Secures Approval In Europe To Conduct A First-in-Human Trial Of RX-3117 In Solid Tumors
2012-01-17,Rexahn Pharmaceuticals Provides Key Goals For 2012
2011-11-04,Rexahn Pharmaceuticals Announces Phase II Results For Serdaxin&#174; As Treatment For Major Depressive Disorder
2011-10-12,Rexahn Pharmaceuticals Granted US Patent For Novel Anti-cancer Isoquinolinamine Compounds
2011-10-03,Rexahn Pharmaceuticals Announces Publication Of Study Validating Mechanism Of Action Of Serdaxin&#174;
2011-09-28,Rexahn Pharmaceuticals Completes Patient Enrollment For Archexin Phase II Clinical Trial In Metastatic Pancreatic Cancer
2011-09-08,Rexahn Pharmaceuticals To Present At The Rodman &amp; Renshaw 13th Annual Healthcare Conference
2011-09-06,Rexahn Pharmaceuticals Announces US Patent Issued For CNS-based Treatment Of Sexual Dysfunction
2011-08-08,European Patent Granted For Neurotherapeutic Compositions
2011-06-22,Rexahn Pharmaceuticals Completes Patient Enrollment In Serdaxin Phase IIb Clinical Trial For Major Depressive Disorder
2011-05-23,Insiders Trading FURX, MELI, FRP
2011-05-05,Rexahn Pharmaceuticals Reports Enrollment Progress On Phase IIb Clinical Trial Of Serdaxin For Depression
2011-04-12,6 Stocks With Big Insider Buying
2011-04-06,Insiders Trading RNN, LULU, KYN, GES
2011-04-04,Rexahn Pharmaceuticals To Present At Needham &amp; Company&#8217;s 10th Annual Healthcare Conference
2011-03-31,Rexahn Closes $10 Million In Registered Direct Offering
2011-03-30,Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-5902 At AACR 102nd Annual Meeting
2011-03-28,Rexahn To Raise $10 Million In Registered Direct Offering
2011-03-23,Rexahn Pharmaceuticals Enrolls 100 Patients In Serdaxin&#174; Phase IIb Clinical Trial For Depression
2011-03-14,Rexahn Pharmaceuticals To Present At The Roth Capital Partners 23rd Annual OC Growth Stock Conference
2011-03-07,Rexahn Announces CEO Transition To CSO And Search For New CEO
2011-02-28,Rexahn Pharmaceuticals Granted European Patent For New Quinoxalinyl-piperazine Compounds
2011-02-18,Biotech Mailbag: BIO CEO Wrap
2011-02-11,Biotech Stock Mailbag: Protalix BioTherapeutics
2011-02-08,Rexahn Higher on Deja Vu Stock Promotion
2011-02-01,6 Penny Stocks for the Biotech Boom
2011-01-25,Rexahn Pharmaceuticals Enrolls First Patient In Serdaxin&#174; Phase IIb Clinical Trial
2011-01-24,Genoptix, Clinical Data: Small-Cap Winners
2011-01-20,Wendy's/Arby's, BioLase: Small-Cap Winners
2011-01-20,Teva Pharmaceutical Increases Its Investment In Rexahn For The Continued Research And Development Of The Pre-Clinical Anti-Cancer Compound, RX-3117
2010-12-20,Rexahn Awarded Patent In Japan For RX-0047
2010-12-08,Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data At The American College Of Neuropsychopharmacologists Annual Meeting
2010-12-06,U.S. Patent Issued For New Method For Treating Cognitive Disorders
2010-11-22,Additional U.S. Patent Issued For Rexahn&#8217;s CNS Treatment Portfolio
2010-11-08,Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anticancer Compounds
2010-11-04,Rexahn Awarded Qualifying Therapeutic Discovery Project Grants To Further Develop Anti-Cancer, Depression, And Erectile Dysfunction Treatments
2010-10-26,Rexahn To Use MedAvante Centralized Ratings In MDD Phase 2b Study
2010-10-20,Rexahn Pharmaceuticals To Attend BioNetwork West
2010-10-19,Rexahn Pharmaceuticals Publishes New Data On Anti-Cancer Isoquinolinamine Derivatives
2010-09-21,Rexahn Pharmaceuticals Announces Publication Of Study On Neuroprotective Effects Of Clavulanic Acid
2017-02-27,Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results And Provides Corporate Update
2017-02-23,Rexahn Pharmaceuticals Doses First Patient In A Phase IIa Trial Of Supinoxin™ In Patients With Metastatic Triple Negative Breast Cancer
2017-01-20,Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
2017-01-03,Rexahn Pharmaceuticals To Present At Biotech Showcase™ 2017
2016-11-07,Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-31,Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent
2016-10-26,Rexahn Pharmaceuticals Receives U.S. Patent For RX-21101: A Novel Nano-Polymer Conjugate Of Docetaxel For The Targeted Treatment Of Solid Tumors
2016-10-10,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
2016-10-04,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
2016-09-14,Rexahn Announces $6 Million Registered Direct Offering
2016-09-12,Rexahn Pharmaceuticals Initiates Stage 2 Of Phase Ib/IIa Clinical Trial Of RX-3117 In Relapsed Or Refractory Metastatic Pancreatic Cancer
2016-09-07,Rexahn Pharmaceuticals To Present At 18th Annual Rodman & Renshaw  Global Investment Conference On September 12, 2016
2016-08-08,Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results
2016-07-11,Rexahn Pharmaceuticals Strengthens Leadership Team
2016-06-06,Rexahn Pharmaceuticals Presents Clinical Data For Three Novel Targeted Oncology Programs At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-23,Rexahn Pharmaceuticals To Present At The American Society Of Clinical Oncology (ASCO) 2016 Annual Meeting
2016-05-09,Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-04-20,Rexahn Pharmaceuticals Presents Clinical Trial Results For Archexin® At The 2016 American Association For Cancer Research Annual Meeting
2016-04-13,Rexahn Pharmaceuticals To Present At The 2016 American Association For Cancer Research Annual Meeting
2016-03-29,Rexahn Pharmaceuticals Announces Initiation Of Phase Ib/IIa Clinical Trial Of Its Novel Oral Anti-Cancer Therapeutic RX-3117 In The Treatment Of Pancreatic And Bladder Cancer
2016-03-24,Rexahn Pharmaceuticals Presents Additional Data For Supinoxin For The Treatment Of Triple Negative Breast Cancer At The 2016 Targeted Anticancer Therapeutics Congress
2016-03-14,Rexahn Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results
2016-02-26,Rexahn Announces $5 Million Registered Direct Offering
2016-02-12,8 Biotech Stocks Under $10 Poised for Breakouts
2016-02-08,Rexahn Pharmaceuticals Completes Stage 1 And Begins Enrollment In Stage 2 Of Archexin® Phase IIa Clinical Trial In Metastatic Renal Cell Carcinoma
2016-02-01,Rexahn Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference On Monday, February 8, 2016
2016-01-25,Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations At The 2016 Gastrointestinal Cancers Symposium
2016-01-12,New Preclinical Data For Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition
2016-01-11,Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction In A Phase IIa Clinical Study
2016-01-05,Rexahn Pharmaceuticals To Present At Biotech Showcase™ 2016
2015-12-14,Rexahn Pharmaceuticals Announces New Data For Supinoxin™ Showing Potent Tumor Growth Inhibition
2015-11-11,Rexahn Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference On November 18, 2015
2015-11-06,Rexahn Announces $7.0 Million Registered Direct Offering
2015-11-05,Rexahn Pharmaceuticals Reports Interim Clinical Data For Archexin® At The 14th International Kidney Cancer Symposium
2015-11-04,4 Stocks Under $10 Making Big Up Moves on Big Volume
2015-11-03,Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-26,Rexahn Pharmaceuticals Receives U.S. Patent for RX-3117 Anti-Cancer Program
2015-10-14,Rexahn Pharmaceuticals To Present At The 14th Annual BIO Investor Forum
2015-09-28,Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015
2015-09-25,Rexahn Pharmaceuticals To Present Preliminary Clinical Data At The European Cancer Congress 2015
2015-09-23,Rexahn Pharmaceuticals To Present At The 15th Annual Biotech In Europe Investor Forum
2015-09-08,Rexahn Pharmaceuticals To Present At The Biopharm America(TM) 2015 Conference In Boston
2015-08-31,Rexahn Pharmaceuticals To Present At The 17th Annual Rodman And Renshaw Global Investment Conference On September 10, 2015
2015-08-10,Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-14,Rexahn Pharmaceuticals Awarded Patent In Japan For Novel Targeted Cancer Drug Delivery Platform
2015-06-22,Rexahn Announces The Appointment Of Peter Brandt As Chairman Of The Board
2015-06-09,Data On Rexahn's RX-3117 In Non-Small Cell Lung Cancer Presented At 16th International Symposium Of The Purine And Pyrimidine Society
2015-06-08,National Cancer Institute Accepts Rexahn's RX-21101 For Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program
2015-05-29,5 Stocks Under $10 Ready to Spike Higher
2015-05-13,Rexahn Announces Poster Presentations At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
2015-05-11,Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results And Pipeline Update
2015-04-21,New Data Show Rexahn's Supinoxin(TM) Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model
2015-04-20,Rexahn Identifies RX-3117 Biomarker & Presents Data At The 2015 American Association For Cancer Research Annual Meeting
2015-04-13,Rexahn Pharmaceuticals To Present Data On RX-3117 And Supinoxin(TM) At The 2015 American Association For Cancer Research Annual Meeting
2015-03-18,Rexahn Pharmaceuticals To Present At The 12th Annual BIO Asia International Conference In Tokyo, Japan
2015-03-17,Rexahn Pharmaceuticals Reports Fourth Quarter And Full-Year 2014 Financial Results And Pipeline Update
2015-03-04,Rexahn Pharmaceuticals To Present At The BIO-Europe Spring(R) 2015 Conference In Paris, France
2015-03-02,Rexahn Pharmaceuticals To Present At The ROTH Capital Partners 27th Annual Growth Stock Conference
2015-02-18,Rexahn Pharmaceuticals To Present At The 3rd Annual Sachs Cancer Bio Partnering & Investment Forum In New York
2015-02-09,Rexahn Pharmaceuticals Announces The Publication Of Preclinical Data For Supinoxin(TM) (RX-5902) Demonstrating Mechanism Of Action
2015-02-04,Rexahn Pharmaceuticals Announces The Appointment Of Ely Benaim, M.D., As Chief Medical Officer
2015-02-02,Rexahn Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-07,Rexahn Pharmaceuticals To Present At Biotech Showcase(TM) 2015
2015-01-06,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells
2014-12-04,Rexahn Pharmaceuticals To Present At The Oppenheimer Healthcare Conference On December 10, 2014
2014-12-03,Rexahn Pharmaceuticals Appoints Richard Rodgers To Its Board Of Directors
2014-11-17,Rexahn Pharmaceuticals To Participate In Brean Capital 2014 Life Sciences Summit
2014-11-13,Rexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results And Pipeline Update
2014-11-11,Rexahn Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference On November 18, 2014
2014-10-28,Rexahn Pharmaceuticals To Present At The BIO-Europe(R) Conference In Frankfurt, Germany
2014-09-30,Rexahn Pharmaceuticals To Present At 13th Annual BIO Investor Forum
2014-09-24,Rexahn Receives FDA Orphan Drug Designation For RX-3117 In Treatment Of Pancreatic Cancer
2014-09-23,Rexahn Pharmaceuticals To Present At The 14th Annual Biotech In Europe Investor Forum For Global Partnering And Investment In Basel, Switzerland
2014-09-16,Rexahn Pharmaceuticals To Present At The BioPharm America™ 2014 In Boston, Massachusetts, USA
2014-09-04,Rexahn Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference On September 9, 2014
2014-09-03,Rexahn Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform
2014-08-14,Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results And Pipeline Update
2014-07-18,Rexahn Pharmaceuticals Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors
2014-05-15,Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results And Pipeline Update
2014-05-08,RX-3117 Showed Greater Efficacy (tumor Growth Inhibition) As Compared To Gemcitabine In Four Different Xenograft Animal Models With Gemcitabine Resistant Human Cancer Cell Lines: Colorectal Cancer (Colo205), Small Cell Lung Cancer (H69), Cervical Cancer (CaSki) And Pancreatic Cancer (CTG-0298).
2014-04-21,Rexahn Presents Data From Preclinical Studies Of RX-21101
2014-04-02,Rexahn Pharmaceuticals To Present Data On RX-3117 And RX-21101 At The 2014 American Association For Clinical Research Annual Meeting
2014-03-24,Rexahn Pharmaceuticals Reports Fourth Quarter And Full-Year 2013 Financial Results And Recent Highlights
2014-03-19,3 Stocks Under $10 Making Big Moves
2014-03-17,Rexahn Pharmaceuticals To Present At The 2nd Annual Sachs Cancer Bio Partnering &amp; Investment Forum In New York
2014-03-11,Rexahn Announces Initial Results From Phase I Trial Of SupinoxinTM (RX-5902) For Solid Cancer Tumors
2014-03-07,Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
2014-03-04,Rexahn Pharmaceuticals To Present At The 26th Annual ROTH Conference
2014-03-03,Rexahn Pharmaceuticals Appoints Mark Carthy To Board Of Directors
2014-03-01,Biotech Sector Performance February 2014: Red Hot But...
2014-02-26,4 Biotech Stocks Under $10 Moving Higher
2014-02-06,5 Stocks Under $10 Set to Soar
2014-02-04,Rexahn Pharmaceuticals To Present At The 16th Annual BIO CEO &amp; Investor Conference
2014-01-31,4 Health Care Stocks Under $10 to Watch
2014-01-21,It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
2014-01-15,Rexahn Announces $20 Million Registered Direct Offering
2014-01-14,Rexahn Initiates Phase IIa Clinical Trial Of Archexin&#174; In Patients With Metastatic Renal Cell Carcinoma
2014-01-10,Why Rexahn Pharmaceuticals (RNN) Is Up Today
2014-01-08,Rexahn Initiates Phase Ib Clinical Trial Of RX-3117 For Treatment Of Solid Tumors
2014-01-07,Rexahn Pharmaceuticals To Present At The Biotech Showcase 2014
2013-12-11,Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin TM&#160;(RX-5902)
2013-11-19,Rexahn Pharmaceuticals To Participate In Brean Capital 2013 Life Sciences Summit
2013-11-14,Rexahn Pharmaceuticals Reports Third Quarter Financial Results And Pipeline Update
2013-10-11,Rexahn Announces $5.3 Million At Market Registered Direct Offering
2013-10-10,Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform From Ohio State University
2013-10-03,5 Stocks Under $10 Set to Soar
2013-09-30,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For Novel Anti-Cancer Compound RX-3117
2013-09-12,Rexahn Awarded Patent In Europe For Cancer Drug Archexin&#174;
2013-09-05,Rexahn Pharmaceuticals To Present At The 15th Annual Rodman &amp; Renshaw Global Investment Conference On September 9, 2013
2013-09-04,Rexahn Pharmaceuticals Provides A Clinical Development And Financial Update
2013-08-28,Rexahn Pharmaceuticals Announces Teva Will Not Exercise Its Option To License RX-3117
2013-08-07,Rexahn Pharmaceuticals Initiates Dosing In Phase I Trial Of SupinoxinTM (RX-5902) A Candidate For Treating Solid Cancer Tumors
2013-07-24,Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering
2013-07-17,Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform
2013-07-15,Rexahn Pharmaceuticals Announce IND Submission For RX-3117
2013-07-09,Rexahn Pharmaceuticals Awarded Patent In Japan For Novel Anti-cancer Isoquinolinamine Compounds&#160;&#160;
2013-06-17,Rexahn Awarded U.S. Patent For Novel Anti-Cancer Compounds
2013-05-20,Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Conference
2013-03-11,Rexahn Pharmaceuticals To Present At The 25th Annual ROTH Conference
2013-02-19,Rexahn Pharmaceuticals Provides Key Goals For 2013
2013-01-22,Rexahn Pharmaceuticals Appoints Peter D. Suzdak As Chief Executive Officer
2012-12-17,Rexahn Pharmaceuticals Expands Its Intellectual Property Around Class Of Potent Anti-cancer Isoquinolinamine Compounds
2012-12-04,Rexahn Pharmaceuticals Closes Public Offering For $6,600,000 In Gross Proceeds
2012-11-29,Rexahn Pharmaceuticals Prices Public Offering Of Stock
2012-11-28,Rexahn Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrant
2012-11-28,Teva Pharmaceutical To Increase Ownership In Rexahn
2012-11-21,Rexahn Pharmaceuticals Issued US Patent For Quinoxalinyl-piperazine Compounds
2012-09-26,Rexahn Pharmaceuticals Granted European Patent For Novel Anti-cancer Isoquinolinamine Compounds
2012-09-06,Rexahn Pharmaceuticals To Present At The Rodman &amp; Renshaw 14th Annual Healthcare Conference
2012-09-04,Rexahn Pharmaceuticals Provides Update On 2012 Strategic Goals
2012-08-31,Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta
2012-08-30,Rexahn Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
2012-08-28,Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data For Archexin In Patients With Metastatic Pancreatic Cancer
2012-08-06,Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study Of RX-3117
2012-07-02,Rexahn Submits An Investigational New Drug Application To The FDA For First-in-Class P68 Helicase Inhibitor, RX-5902
2012-05-30,Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anti-Cancer Compound RX-3117
2012-05-08,Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA
2012-03-27,Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-3117 At AACR 103rd Annual Meeting
2012-03-13,Rexahn Pharmaceuticals Enrolls First Subject In Exploratory Phase I Clinical Study Of RX-3117
2012-01-25,Rexahn Pharmaceuticals Publishes New Preclinical Data For Quinoxalinyl-Piperazine Compounds
2012-01-18,Rexahn Pharmaceuticals Secures Approval In Europe To Conduct A First-in-Human Trial Of RX-3117 In Solid Tumors
2012-01-17,Rexahn Pharmaceuticals Provides Key Goals For 2012
2011-11-04,Rexahn Pharmaceuticals Announces Phase II Results For Serdaxin&#174; As Treatment For Major Depressive Disorder
2011-10-12,Rexahn Pharmaceuticals Granted US Patent For Novel Anti-cancer Isoquinolinamine Compounds
2011-10-03,Rexahn Pharmaceuticals Announces Publication Of Study Validating Mechanism Of Action Of Serdaxin&#174;
2011-09-28,Rexahn Pharmaceuticals Completes Patient Enrollment For Archexin Phase II Clinical Trial In Metastatic Pancreatic Cancer
2011-09-08,Rexahn Pharmaceuticals To Present At The Rodman &amp; Renshaw 13th Annual Healthcare Conference
2011-09-06,Rexahn Pharmaceuticals Announces US Patent Issued For CNS-based Treatment Of Sexual Dysfunction
2011-08-08,European Patent Granted For Neurotherapeutic Compositions
2011-06-22,Rexahn Pharmaceuticals Completes Patient Enrollment In Serdaxin Phase IIb Clinical Trial For Major Depressive Disorder
2011-05-23,Insiders Trading FURX, MELI, FRP
2011-05-05,Rexahn Pharmaceuticals Reports Enrollment Progress On Phase IIb Clinical Trial Of Serdaxin For Depression
2011-04-12,6 Stocks With Big Insider Buying
2011-04-06,Insiders Trading RNN, LULU, KYN, GES
2011-04-04,Rexahn Pharmaceuticals To Present At Needham &amp; Company&#8217;s 10th Annual Healthcare Conference
2011-03-31,Rexahn Closes $10 Million In Registered Direct Offering
2011-03-30,Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-5902 At AACR 102nd Annual Meeting
2011-03-28,Rexahn To Raise $10 Million In Registered Direct Offering
2011-03-23,Rexahn Pharmaceuticals Enrolls 100 Patients In Serdaxin&#174; Phase IIb Clinical Trial For Depression
2011-03-14,Rexahn Pharmaceuticals To Present At The Roth Capital Partners 23rd Annual OC Growth Stock Conference
2011-03-07,Rexahn Announces CEO Transition To CSO And Search For New CEO
2011-02-28,Rexahn Pharmaceuticals Granted European Patent For New Quinoxalinyl-piperazine Compounds
2011-02-18,Biotech Mailbag: BIO CEO Wrap
2011-02-11,Biotech Stock Mailbag: Protalix BioTherapeutics
2011-02-08,Rexahn Higher on Deja Vu Stock Promotion
2011-02-01,6 Penny Stocks for the Biotech Boom
2011-01-25,Rexahn Pharmaceuticals Enrolls First Patient In Serdaxin&#174; Phase IIb Clinical Trial
2011-01-24,Genoptix, Clinical Data: Small-Cap Winners
2011-01-20,Wendy's/Arby's, BioLase: Small-Cap Winners
2011-01-20,Teva Pharmaceutical Increases Its Investment In Rexahn For The Continued Research And Development Of The Pre-Clinical Anti-Cancer Compound, RX-3117
2010-12-20,Rexahn Awarded Patent In Japan For RX-0047
2010-12-08,Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data At The American College Of Neuropsychopharmacologists Annual Meeting
2010-12-06,U.S. Patent Issued For New Method For Treating Cognitive Disorders
2010-11-22,Additional U.S. Patent Issued For Rexahn&#8217;s CNS Treatment Portfolio
2010-11-08,Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anticancer Compounds
2010-11-04,Rexahn Awarded Qualifying Therapeutic Discovery Project Grants To Further Develop Anti-Cancer, Depression, And Erectile Dysfunction Treatments
2010-10-26,Rexahn To Use MedAvante Centralized Ratings In MDD Phase 2b Study
2010-10-20,Rexahn Pharmaceuticals To Attend BioNetwork West
2010-10-19,Rexahn Pharmaceuticals Publishes New Data On Anti-Cancer Isoquinolinamine Derivatives
2010-09-21,Rexahn Pharmaceuticals Announces Publication Of Study On Neuroprotective Effects Of Clavulanic Acid
